Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 5 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Vitamins C, E stave off nonalcoholic fatty liver disease/steatohepatitis

26 Dec 2019
Dr Paul Marik claims that an IV drip of Vitamin C, steroids and thiamine, will treat sepsis effectively.

Dietary intake of vitamins C and E may help protect against liver damage associated with nonalcoholic fatty liver disease (NAFLD), a recent study has shown.

Researchers conducted a cross-sectional analysis of 789 participants (mean age, 58.83±6.58 years; 52.6 percent male), in whom NAFLD was detected through ultrasonography. A food frequency questionnaire was used to evaluate nutritional intake.

Majority (73.6 percent; n=581) were able to meet the recommended daily intake level of vitamin C, while only 25.2 percent (n=199) met the same guidelines for vitamin E intake. Fifty-two participants (6.6 percent) used vitamin supplements. Both NAFLD and nonalcoholic steatohepatitis (NASH) occurred at greater frequencies in patients with vitamins C and E intake <1,000 kcal.

Multivariate logistic regression analysis found that in the upper tertile of vitamin E intake, each additional 1,000-kcal of vitamin E correlated with a significant drop in the risk of NASH (odds ratio [OR], 0.64, 95 percent confidence interval [CI], 0.43–0.94; p=0.024). No effect was reported for NAFLD or presumed fibrosis.

The same was true for reaching the recommended intake levels of vitamin E (OR, 0.48, 95 percent CI, 0.30–0.77; p=0.002).

Vitamin C also exerted a protective effect. In the upper tertile of intake levels, every additional 1,000-kcal of vitamin C reduced the likelihood of both NAFLD (OR, 0.68, 95 percent CI, 0.47–0.99; p=0.045) and NASH (OR, 0.57, 95 percent CI, 0.38–0.84; p=0.004). However, satisfying the recommended intake levels did not seem to yield a significant benefit.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 5 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.